Diagnostics 2035: The Next Decade Of Testing Innovation

The diagnostics landscape is poised for dramatic transformation over the next decade, driven by advances in liquid biopsy technologies, AI-powered interpretation, point-of-care testing capabilities, and multi-omics integration that promise to fundamentally reshape how diseases are detected, monitored, and managed. These innovations extend beyond incremental improvements to enable entirely new paradigms including pre-symptomatic disease detection, real-time health monitoring, and personalized treatment optimization based on molecular signatures.

Understanding the trajectory of diagnostics innovation requires looking beyond current technological capabilities to assess which advances will achieve clinical validation, regulatory approval, and sustainable reimbursement by 2035. The convergence of genomics, proteomics, metabolomics, and artificial intelligence is creating unprecedented opportunities for early disease detection and precision medicine, yet realizing this potential depends on overcoming significant challenges in clinical evidence generation, cost reduction, and integration into existing healthcare workflows.

Join us to discuss:

• What diagnostic technologies and approaches are most likely to fundamentally transform disease detection and monitoring by 2035, and what scientific and commercial milestones must be achieved?
• How will the economics of diagnostics evolve as technologies advance, and what reimbursement models will be needed to support widespread adoption of next-generation testing?
• What clinical validation standards, regulatory pathways, and healthcare system changes are necessary to realize the full potential of diagnostic innovation over the next decade?